Related Experiment Videos

More from CROI...new drugs: full pipeline, steady progress

Charles Flexner

The Hopkins HIV Report : a Bimonthly Newsletter for Healthcare Providers

|June 18, 2003

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Selection of Mutations in HIV-1 Nucleocapsid and Integrase in Individuals Living with HIV Experiencing Virologic Failure After Initiating or Switching to Tenofovir-Lamivudine-Dolutegravir.

medRxiv : the preprint server for health sciences·2026

Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access.

Clinical pharmacology and therapeutics·2026

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study.

The lancet. HIV·2025

The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases.

Annual review of pharmacology and toxicology·2025

Structure-Activity Relationship Studies of Emtricitabine Prodrugs toward Long-Acting Antiretroviral Formulations.

ACS omega·2025

Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites.

Open forum infectious diseases·2025

See all related articles